OA10478A - Nitro-benzamides useful as anti-arrhythmic agents - Google Patents

Nitro-benzamides useful as anti-arrhythmic agents Download PDF

Info

Publication number: OA10478A
Authority: OA; OAPI
Prior art keywords: formula; compound; group; sait; pharmaceutically acceptable
Prior art date: 1994-10-26

Application number

OA60996A

Other languages

English (en)

Inventor

Guy Marguerite Marie Ge Nadler

Michel Jean Roger Martin

Original Assignee

Smithkline Beecham Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-26

Filing date

1997-04-25

Publication date

2002-04-09

1997-04-25 Application filed by Smithkline Beecham Lab filed Critical Smithkline Beecham Lab

2002-04-09 Publication of OA10478A publication Critical patent/OA10478A/en

Links

239000003416 antiarrhythmic agent Substances 0.000 title description 5
KLGQWSOYKYFBTR-UHFFFAOYSA-N 2-nitrobenzamide Chemical class NC(=O)C1=CC=CC=C1[N+]([O-])=O KLGQWSOYKYFBTR-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 113
125000000217 alkyl group Chemical group 0.000 claims abstract description 27
125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 10
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
239000001257 hydrogen Substances 0.000 claims abstract description 10
125000003342 alkenyl group Chemical group 0.000 claims abstract description 9
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 8
229910052799 carbon Inorganic materials 0.000 claims abstract description 8
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 6
125000003545 alkoxy group Chemical group 0.000 claims abstract description 6
125000004429 atom Chemical group 0.000 claims abstract description 6
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 5
125000003118 aryl group Chemical group 0.000 claims abstract description 4
238000004519 manufacturing process Methods 0.000 claims abstract description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 2
229910052760 oxygen Inorganic materials 0.000 claims abstract 2
239000001301 oxygen Substances 0.000 claims abstract 2
238000000034 method Methods 0.000 claims description 14
206010003119 arrhythmia Diseases 0.000 claims description 13
238000011282 treatment Methods 0.000 claims description 9
230000006793 arrhythmia Effects 0.000 claims description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
230000033764 rhythmic process Effects 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 4
238000011321 prophylaxis Methods 0.000 claims description 4
230000000302 ischemic effect Effects 0.000 claims description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
230000001335 demethylating effect Effects 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 claims 1
150000003839 salts Chemical class 0.000 abstract description 7
239000003814 drug Substances 0.000 abstract description 3
125000000623 heterocyclic group Chemical group 0.000 abstract description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
125000001424 substituent group Chemical group 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
239000000203 mixture Substances 0.000 description 17
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 10
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
230000036982 action potential Effects 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 7
229940073584 methylene chloride Drugs 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
-1 hydrochloric Chemical class 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
239000002585 base Substances 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000010992 reflux Methods 0.000 description 5
239000002904 solvent Substances 0.000 description 5
230000000747 cardiac effect Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
150000007530 organic bases Chemical class 0.000 description 4
239000000725 suspension Substances 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
206010047281 Ventricular arrhythmia Diseases 0.000 description 3
125000002947 alkylene group Chemical group 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
229960004132 diethyl ether Drugs 0.000 description 3
239000000945 filler Substances 0.000 description 3
238000011049 filling Methods 0.000 description 3
239000012442 inert solvent Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
210000003540 papillary muscle Anatomy 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
229960001866 silicon dioxide Drugs 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
GWHABAVIHQZMSK-UHFFFAOYSA-N 3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]propanamide Chemical compound COC1=CC=C(CCN(C)CCC(N)=O)C=C1OC GWHABAVIHQZMSK-UHFFFAOYSA-N 0.000 description 2
SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
239000013078 crystal Substances 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000012280 lithium aluminium hydride Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002336 repolarization Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000002110 toxicologic effect Effects 0.000 description 2
231100000759 toxicological effect Toxicity 0.000 description 2
230000002861 ventricular Effects 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
ANOUKFYBOAKOIR-UHFFFAOYSA-N 3,4-dimethoxyphenylethylamine Chemical compound COC1=CC=C(CCN)C=C1OC ANOUKFYBOAKOIR-UHFFFAOYSA-N 0.000 description 1
JQDXZJYAUSVHDH-UHFFFAOYSA-N 3-chloropropanamide Chemical compound NC(=O)CCCl JQDXZJYAUSVHDH-UHFFFAOYSA-N 0.000 description 1
ZESWUEBPRPGMTP-UHFFFAOYSA-N 4-nitrobenzamide Chemical class NC(=O)C1=CC=C([N+]([O-])=O)C=C1 ZESWUEBPRPGMTP-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
206010003671 Atrioventricular Block Diseases 0.000 description 1
101150041968 CDC13 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000010271 Heart Block Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000288147 Meleagris gallopavo Species 0.000 description 1
150000001204 N-oxides Chemical class 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
208000004301 Sinus Arrhythmia Diseases 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
229940054066 benzamide antipsychotics Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
HOPSCVCBEOCPJZ-UHFFFAOYSA-N carboxymethyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)=O HOPSCVCBEOCPJZ-UHFFFAOYSA-N 0.000 description 1
206010061592 cardiac fibrillation Diseases 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
230000008828 contractile function Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
230000002600 fibrillogenic effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229940085918 formadon Drugs 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
239000005457 ice water Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
JWANNLXCVGJLAS-UHFFFAOYSA-N n'-[2-(3,4-dimethoxyphenyl)ethyl]-n'-methylpropane-1,3-diamine Chemical compound COC1=CC=C(CCN(C)CCCN)C=C1OC JWANNLXCVGJLAS-UHFFFAOYSA-N 0.000 description 1
CRFHVQRXGDHOFE-UHFFFAOYSA-N n-(3-chloropropyl)-4-nitrobenzamide Chemical compound [O-][N+](=O)C1=CC=C(C(=O)NCCCCl)C=C1 CRFHVQRXGDHOFE-UHFFFAOYSA-N 0.000 description 1
QLUVAVFNMRXIIZ-UHFFFAOYSA-N n-[3-[2-(3,4-dimethoxyphenyl)ethylamino]propyl]-4-nitrobenzamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CCNCCCNC(=O)C1=CC=C([N+]([O-])=O)C=C1 QLUVAVFNMRXIIZ-UHFFFAOYSA-N 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
208000008510 paroxysmal tachycardia Diseases 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
235000003270 potassium fluoride Nutrition 0.000 description 1
239000011698 potassium fluoride Substances 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
230000001536 pro-arrhythmogenic effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000007789 sealing Methods 0.000 description 1
229920000260 silastic Polymers 0.000 description 1
210000001013 sinoatrial node Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Heart & Thoracic Surgery (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

OA60996A 1994-10-26 1997-04-25 Nitro-benzamides useful as anti-arrhythmic agents OA10478A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9412806A FR2726267B1 (fr)	1994-10-26	1994-10-26	Nouveaux agents anti-arythmiques, compositions pharmaceutiques les contenant, et procede pour les preparer

Publications (1)

Publication Number	Publication Date
OA10478A true OA10478A (en)	2002-04-09

Family

ID=9468229

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA60996A OA10478A (en)	1994-10-26	1997-04-25	Nitro-benzamides useful as anti-arrhythmic agents

Country Status (35)

Country	Link
US (3)	US5977179A (fr)
EP (1)	EP0788474B1 (fr)
JP (1)	JPH10508013A (fr)
KR (1)	KR100369958B1 (fr)
CN (1)	CN1071740C (fr)
AP (1)	AP694A (fr)
AT (1)	ATE192428T1 (fr)
AU (1)	AU697357B2 (fr)
BG (1)	BG63367B1 (fr)
BR (1)	BR9509432A (fr)
CA (1)	CA2203814A1 (fr)
CZ (1)	CZ290326B6 (fr)
DE (1)	DE69516708T2 (fr)
DK (1)	DK0788474T3 (fr)
DZ (1)	DZ1937A1 (fr)
ES (1)	ES2145306T3 (fr)
FI (1)	FI971755A7 (fr)
FR (1)	FR2726267B1 (fr)
GR (1)	GR3033748T3 (fr)
HU (1)	HU222889B1 (fr)
ID (1)	ID18094A (fr)
IL (1)	IL115732A (fr)
MA (1)	MA23706A1 (fr)
NO (1)	NO971955L (fr)
NZ (1)	NZ295368A (fr)
OA (1)	OA10478A (fr)
PL (1)	PL181936B1 (fr)
PT (1)	PT788474E (fr)
RO (1)	RO117174B1 (fr)
RU (1)	RU2159227C2 (fr)
SK (1)	SK281743B6 (fr)
TR (1)	TR199501320A2 (fr)
UA (1)	UA50722C2 (fr)
WO (1)	WO1996013479A1 (fr)
ZA (1)	ZA958984B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2726267B1 (fr)	1994-10-26	1998-01-02	Smithkline Beecham Lab	Nouveaux agents anti-arythmiques, compositions pharmaceutiques les contenant, et procede pour les preparer
GB9706376D0 (en) *	1997-03-27	1997-05-14	Smithkline Beecham Plc	Novel pharmaceutical
GB9923933D0 (en) *	1999-10-08	1999-12-08	Smithkline Beecham Lab	Novel pharmaceutical
GB9923934D0 (en) *	1999-10-08	1999-12-08	Smithkline Beecham Plc	Novel pharmaceutical
WO2001053288A1 (fr)	2000-01-20	2001-07-26	Eisai Co., Ltd.	Nouveaux composes de piperidine et medicaments contenant ces composes
HK1079703A1 (zh) *	2002-10-11	2006-04-13	巴克斯特国际公司	通过静脉施用卤化挥发性麻醉药保护心脏和保护神经的方法
WO2004078715A1 (fr)	2003-03-07	2004-09-16	Astellas Pharma Inc.	Derive heterocyclique azote contenant du styryl 2,6-disubstitue
RU2415128C2 (ru) *	2009-05-07	2011-03-27	Общество с ограниченной ответственностью "Центр по химии лекарственных средств" (ООО "ЦХЛС-ВНИХФИ")	Гидрохлорид n-1-[(4-фторфенил)-2-(1-этил-4-пиперидил)-этил]-4-нитробензамид, проявляющий антиаритмическую и антифибрилляторную активность
RU2700263C1 (ru) *	2019-05-16	2019-09-16	федеральное государственное автономное образовательное учреждение высшего образования «Национальный исследовательский Томский политехнический университет»	Средство, обладающее антиаритмическим действием

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE242344C (fr)
US3139456A (en) *	1960-07-27	1964-06-30	Searle & Co	Nu-(substituted phenoxyalkyl)-aralkylamines
DE2827801A1 (de) *	1978-06-24	1980-01-10	Kali Chemie Pharma Gmbh	Neue n tief 1 -benzoyl-n tief 2 -phenyl-1,3-diaminopropan-2-ole, verfahren zu deren herstellung und arzneimittel
DE3242344A1 (de) *	1982-11-16	1984-05-17	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue alkylendiaminoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
EG18188A (en) *	1986-05-01	1992-09-30	Pfizer Ltd	Process for preparation anti-arhythmia agents
GB8706662D0 (en) *	1987-03-20	1987-04-23	Pfizer Ltd	Anti-arrhythmia agents
HUT68856A (en) *	1991-01-11	1995-08-28	Glaxo Lab Sa	Acridine derivatives, pharmaceutical compositions comprising the same compouds as effective substances and a process for producing the compounds and the pharmaceutical compositions
US5208252A (en) *	1992-07-24	1993-05-04	Ortho Pharmaceutical Corporation	Aminoethylthiophene derivatives
DE4422517A1 (de) *	1994-06-28	1996-01-04	Dresden Arzneimittel	Neue (2-(3,4-Dimethoxy-phenyl)-ethyl)-(2-phenoxy-ethyl)-amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2196672A1 (fr) *	1994-08-04	1996-02-15	You Sup Chung	Derives d'amines, procedes de production de ces derives et utilisation de ces derives comme anti-arythmisants
FR2726267B1 (fr)	1994-10-26	1998-01-02	Smithkline Beecham Lab	Nouveaux agents anti-arythmiques, compositions pharmaceutiques les contenant, et procede pour les preparer

1994
- 1994-10-26 FR FR9412806A patent/FR2726267B1/fr not_active Expired - Fee Related
1995
- 1995-10-24 AU AU38699/95A patent/AU697357B2/en not_active Ceased
- 1995-10-24 CZ CZ19971252A patent/CZ290326B6/cs not_active IP Right Cessation
- 1995-10-24 ZA ZA958984A patent/ZA958984B/xx unknown
- 1995-10-24 EP EP95937849A patent/EP0788474B1/fr not_active Expired - Lifetime
- 1995-10-24 DE DE69516708T patent/DE69516708T2/de not_active Expired - Lifetime
- 1995-10-24 UA UA97052397A patent/UA50722C2/uk unknown
- 1995-10-24 BR BR9509432A patent/BR9509432A/pt not_active Application Discontinuation
- 1995-10-24 IL IL11573295A patent/IL115732A/xx not_active IP Right Cessation
- 1995-10-24 NZ NZ295368A patent/NZ295368A/xx unknown
- 1995-10-24 US US08/836,019 patent/US5977179A/en not_active Expired - Fee Related
- 1995-10-24 KR KR1019970702734A patent/KR100369958B1/ko not_active Expired - Fee Related
- 1995-10-24 RU RU97108129/04A patent/RU2159227C2/ru not_active IP Right Cessation
- 1995-10-24 RO RO97-00764A patent/RO117174B1/ro unknown
- 1995-10-24 AP APAP/P/1997/000965A patent/AP694A/en active
- 1995-10-24 CA CA002203814A patent/CA2203814A1/fr not_active Abandoned
- 1995-10-24 ES ES95937849T patent/ES2145306T3/es not_active Expired - Lifetime
- 1995-10-24 MA MA24051A patent/MA23706A1/fr unknown
- 1995-10-24 PT PT95937849T patent/PT788474E/pt unknown
- 1995-10-24 PL PL95319904A patent/PL181936B1/pl not_active IP Right Cessation
- 1995-10-24 DZ DZ950119A patent/DZ1937A1/fr active
- 1995-10-24 AT AT95937849T patent/ATE192428T1/de not_active IP Right Cessation
- 1995-10-24 DK DK95937849T patent/DK0788474T3/da active
- 1995-10-24 SK SK505-97A patent/SK281743B6/sk unknown
- 1995-10-24 CN CN95196835A patent/CN1071740C/zh not_active Expired - Fee Related
- 1995-10-24 HU HU9702023A patent/HU222889B1/hu not_active IP Right Cessation
- 1995-10-24 ID IDP952198A patent/ID18094A/id unknown
- 1995-10-24 JP JP8514308A patent/JPH10508013A/ja not_active Withdrawn
- 1995-10-24 WO PCT/EP1995/004203 patent/WO1996013479A1/fr not_active Ceased
- 1995-10-26 TR TR95/01320A patent/TR199501320A2/xx unknown
1997
- 1997-04-24 FI FI971755A patent/FI971755A7/fi unknown
- 1997-04-25 OA OA60996A patent/OA10478A/en unknown
- 1997-04-25 NO NO971955A patent/NO971955L/no not_active Application Discontinuation
- 1997-05-20 BG BG101501A patent/BG63367B1/bg unknown
2000
- 2000-06-22 GR GR20000401443T patent/GR3033748T3/el not_active IP Right Cessation
2001
- 2001-04-02 US US09/825,187 patent/US20010025054A1/en not_active Abandoned
2002
- 2002-01-30 US US10/060,760 patent/US6570037B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
FR2726267A1 (fr)	1996-05-03
MX9703112A (es)	1997-07-31
HK1002764A1 (en)	1998-09-18
ID18094A (id)	1998-02-26
SK50597A3 (en)	1997-11-05
PL181936B1 (pl)	2001-10-31
AP694A (en)	1998-11-18
US6570037B2 (en)	2003-05-27
RU2159227C2 (ru)	2000-11-20
NO971955L (no)	1997-06-25
SK281743B6 (sk)	2001-07-10
HUT77004A (hu)	1998-03-02
RO117174B1 (ro)	2001-11-30
FI971755A0 (fi)	1997-04-24
AU3869995A (en)	1996-05-23
ATE192428T1 (de)	2000-05-15
FI971755A7 (fi)	1997-06-23
US20020107243A1 (en)	2002-08-08
UA50722C2 (uk)	2002-11-15
PT788474E (pt)	2000-08-31
CA2203814A1 (fr)	1996-05-09
NO971955D0 (no)	1997-04-25
DE69516708D1 (de)	2000-06-08
BG101501A (en)	1998-01-30
JPH10508013A (ja)	1998-08-04
CZ290326B6 (cs)	2002-07-17
US5977179A (en)	1999-11-02
MA23706A1 (fr)	1996-07-01
US20010025054A1 (en)	2001-09-27
DZ1937A1 (fr)	2002-02-17
AU697357B2 (en)	1998-10-01
AP9700965A0 (en)	1997-04-30
DE69516708T2 (de)	2000-09-28
HU222889B1 (hu)	2003-12-29
BG63367B1 (bg)	2001-11-30
PL319904A1 (en)	1997-09-01
CN1170402A (zh)	1998-01-14
EP0788474B1 (fr)	2000-05-03
KR100369958B1 (ko)	2003-04-08
GR3033748T3 (en)	2000-10-31
BR9509432A (pt)	1998-01-06
IL115732A (en)	2000-08-31
CZ125297A3 (en)	1997-10-15
IL115732A0 (en)	1996-05-14
EP0788474A1 (fr)	1997-08-13
DK0788474T3 (da)	2000-09-11
FR2726267B1 (fr)	1998-01-02
NZ295368A (en)	1998-12-23
TR199501320A2 (tr)	1996-06-21
ES2145306T3 (es)	2000-07-01
WO1996013479A1 (fr)	1996-05-09
ZA958984B (en)	1997-04-24
CN1071740C (zh)	2001-09-26

Publication	Publication Date	Title
OA10478A (en)	2002-04-09	Nitro-benzamides useful as anti-arrhythmic agents
KR20180134675A (ko)	2018-12-19	시클로프로필아민 유도체 화합물 및 이의 용도
EP2486925A1 (fr)	2012-08-15	Agent thérapeutique de l'infarctus cérébral
JP5372514B2 (ja)	2013-12-18	新規なインドリジン誘導体、この調製方法およびこれを含む治療組成物
EP0719263B1 (fr)	1998-07-15	Derives heterocycliques de carboxamide ayant une activite antiarythmique
HK1002764B (en)	2001-01-12	Nitro-benzamides useful as anti-arrhythmic agents
US5712284A (en)	1998-01-27	Azalicyclooctane derivatives as anti-arrhythmic agents
WO1995007884A1 (fr)	1995-03-23	Derives alcanediamine et leur utilisation dans le traitement de l'arythmie et des troubles du rythme ischemique
WO1996027595A1 (fr)	1996-09-12	Heterocyclylcarboxamides et autres composes utilises pour le traitement des arythmies cardiaques
FR2705674A1 (fr)	1994-12-02	Nouveaux composés et leur procédé de préparation et leur utilisation en tant que médicaments.
FR2729144A1 (fr)	1996-07-12	Nouvelles diamines, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu' agents anti-arythmiques
FR2705675A1 (fr)	1994-12-02	Nouveaux composés, leur procédé de préparation et leur utilisation en tant que médicaments.
MXPA97003112A (en)	1997-12-01	Nitro-benzamides useful as agentesantiarritmi
FR2729140A1 (fr)	1996-07-12	Nouveaux derives d'amine, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu'agents anti-arythmiques
FR2729146A1 (fr)	1996-07-12	Nouveaux derives d'amine, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu'agents anti-arythmiques
FR2710069A1 (fr)	1995-03-24	Nouveaux composés, leur procédé de préparation et leur utilisation en tant que médicaments.
FR2708607A1 (fr)	1995-02-10	Nouveaux composés, leur procédé de préparation et leur utilisation en tant que médicaments.
FR2729139A1 (fr)	1996-07-12	Nouveaux derives d'amine, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu'agents anti-arythmiques
FR2729143A1 (fr)	1996-07-12	Nouveaux derives d'amine, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu'agents anti-arythmiques